Choi 1995.

Study characteristics
Methods	Study design: parallel randomized controlled clinical trial Randomization ratio: 1:1:1 (KRG: 30; placebo: 30; trazodon: 30) Dates when study was conducted: April 1994 to September 1994 Setting/country: outpatient/ single center/ S. Korea
Participants	Inclusion criteria: participants with ED classified as type I and type IIb by radioisotope audio‐visual stimulation (AVS)‐penogram Exclusion criteria: organic dysfunction Baseline characteristics of participants ‐ the number of participants randomized: 90 (KRG: 30; placebo: 30; trazodon: 30) ‐ the number of participants analyzed: 90 (KRG: 30; placebo: 30; trazodon: 30) ‐ age (mean): KRG: 42.8; placebo: 45.2; trazodon: 43.2 ‐ comorbidity: NR ‐ ED severity: NR ‐ Psychogenic ED: 81 (90%); mild vasculogenic: 9 (10%, 3 participants per group)
Interventions	Details of intervention and control ‐ Experiment: Korean red ginseng (1800 mg/day [6 tablets of 300 mg, the frequency NR]) (commercial product from KT&G) ‐ Control: placebo; trazodon (25 mg daily at bedtime) Number of study centres: 1 Run‐in period: no Follow‐up period: 12 weeks
Outcomes	1) Erectile function Frequency and duration of erection Morning erections Rigidity and girth of penile shaft during erection Participant and partner satisfaction How measured: questioning participants and their partners Time points measured: at baseline, 4 weeks, 8 weeks and 12 weeks Time points reported: at baseline and 12 weeks 2) Complications How measured: NR Time points measured: at baseline, 4 weeks, 8 weeks and 12 weeks Time points reported: likely cumulative
Funding sources	KT&G Corp. This was noted in the Korean version of the paper.
Declarations of interest	NR
Notes	Publication language: English
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "The patients... were randomly assigned into three groups." Comment: no explicit explanation of the sequence generation.
Allocation concealment (selection bias)	Unclear risk	Comment: no detailed information about allocation concealment.
Blinding of participants and personnel (performance bias)	Unclear risk	Comment: not described.
Blinding of outcome assessment (detection bias) Subjective outcomes	Unclear risk	Comment: not described.
Blinding of outcome assessment (detection bias) Objective outcome: adverse events	Low risk	Comment: objective outcome was not likely affected by lack of blinding.
Incomplete outcome data (attrition bias) Erectile function and sexual satisfaction	Low risk	Quote: "All patients received drugs for three months. A total of 90 patients with 30 patients in each group were closely followed." Comment: all participants who were randomized were included in analysis.
Incomplete outcome data (attrition bias) Adverse events	Low risk	Quote: "All patients received drugs for three months. A total of 90 patients with 30 patients in each group were closely followed." Comment: all participants who were randomized were included in analysis.
Incomplete outcome data (attrition bias) Ability to have intercourse reported by participants (or partner)	Low risk	Quote: "All patients received drugs for three months. A total of 90 patients with 30 patients in each group were closely followed." Comment: all participants who were randomized were included in analysis.
Incomplete outcome data (attrition bias) QoL	Unclear risk	Comment: not measured.
Selective reporting (reporting bias)	Unclear risk	Comment: insufficient information available to permit a judgement and there was no published protocol.
Other bias	Unclear risk	Comment: the severity of erectile dysfunction at baseline was not reported between the study groups.